What is BriaCell Therapeutics Corp. Warrant (BCTXZ)?

BriaCell Therapeutics Corp. Warrant (BCTXZ) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of BCTXZ?

The current price of BCTXZ is $0.14. Prices are updated in real time on Stocks360.

What is BCTXZ's price-to-earnings (PE) ratio?

BCTXZ's trailing twelve-month PE ratio is -0.28, based on current price and earnings per share data available on Stocks360.

What is BCTXZ's market capitalization?

BCTXZ's market capitalization is $254,305.00, placing it in the small-cap tier.

BriaCell Therapeutics Corp. Warrant (BCTXZ)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$0.14

Market Cap

$254.31K

PE (TTM)

-0.28

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.54

Day Range

$0.14 – $0.15

52-wk Range

$0.06 – $0.44

Avg Volume

N/A

Volume

10.48K

BriaCell Therapeutics Corp. Warrant (BCTXZ) is a publicly traded company in the Healthcare sector. Latest price: $0.14. Market cap $254.31K. Trailing PE -0.28. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 4 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

1-Year Price

2025-10-30 · $0.40 2026-10-27 · $0.14 (-66.29%)

Proprietary Signals

Signal snapshot temporarily unavailable.

About BriaCell Therapeutics Corp. Warrant

BriaCell Therapeutics Corp., a biotechnology company based in West Vancouver, Canada, is intensely focused on immuno-oncology, dedicated to engineering novel immunotherapies for cancer treatment. Its flagship compound, Bria-IMT, is a whole-cell cancer vaccine presently in Phase I/IIa clinical development, where it's being evaluated in conjunction with the investigational immunotherapy retifanlimab. The company's pipeline also includes Bria-OTS, a personalized, ready-to-use immunotherapy intended for advanced breast cancer, and BriaDx, a diagnostic tool for determining patient HLA types. BriaCell maintains a non-exclusive clinical trial collaboration with Incyte Corporation to explore the effects of combining various novel clinical candidates. Furthermore, a cooperative research and development agreement with the National Cancer Institute supports preclinical efforts to advance and test Bria-OTS cellular immunotherapy as a cancer therapy.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.28×
P/S (TTM)	0.00×
P/B	1.05×
P/FCF (TTM)	-0.98×
EV / EBITDA	-0.74×
EV / Sales	0.00×
Earnings Yield	-121.70%
Free Cash Flow Yield	-102.40%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$23.34M
Net Income (TTM)	-$36.78M
Free Cash Flow (TTM)	-$30.79M
Net Debt	-$6.88M
Working Capital	$21.80M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-147.92%
Return on Invested Capital	-136.31%